Search Results

SR-3335 5mg  | ≥99%

CSNpharm

SR3335 can selectively bind to RORα and competitively inhibit the binding of 25-hydroxycholesterol to the ligand binding domain with Ki of 220 nM.

More Information Supplier Page

SR-3335 10mg  | ≥99%

CSNpharm

SR3335 can selectively bind to RORα and competitively inhibit the binding of 25-hydroxycholesterol to the ligand binding domain with Ki of 220 nM.

More Information Supplier Page

SR-3335 1mg  | ≥99%

CSNpharm

SR3335 can selectively bind to RORα and competitively inhibit the binding of 25-hydroxycholesterol to the ligand binding domain with Ki of 220 nM.

More Information Supplier Page

SR-3335 25mg  | ≥99%

CSNpharm

SR3335 can selectively bind to RORα and competitively inhibit the binding of 25-hydroxycholesterol to the ligand binding domain with Ki of 220 nM.

More Information Supplier Page

PRT4165 100mg  | ≥98%

CSNpharm

PRT4165, an inhibitor of bim1 and ring1A, could block PRC1 (Polycomb-repressive complex 1)-mediated H2A ubiquitylation.

More Information Supplier Page

PRT4165 25mg  | ≥98%

CSNpharm

PRT4165, an inhibitor of bim1 and ring1A, could block PRC1 (Polycomb-repressive complex 1)-mediated H2A ubiquitylation.

More Information Supplier Page

MCC950 Sodium 50mg  | ≥99%

CSNpharm

MCC950 Sodium is a potent and highly specific small molecule inhibitor of NLRP3 inflammasome with IC50 of 7.5 nM in BMDMs.

More Information Supplier Page

MCC950 Sodium 10mg  | ≥99%

CSNpharm

MCC950 Sodium is a potent and highly specific small molecule inhibitor of NLRP3 inflammasome with IC50 of 7.5 nM in BMDMs.

More Information Supplier Page

MCC950 Sodium 25mg  | ≥99%

CSNpharm

MCC950 Sodium is a potent and highly specific small molecule inhibitor of NLRP3 inflammasome with IC50 of 7.5 nM in BMDMs.

More Information Supplier Page